

# CHUGAI PHARMACEUTICAL CO LTD

ISIN: JP3519400000 WKN: 4519 Asset Class: Stock

## Company

2024/04/23 08:00:00



**Price**  
**5,185.00**  
JPY

**Difference** ▲ 0.68%(35.00)



## Contact Details

CHUGAI PHARMACEUTICAL CO.  
LTD.

Tel: +81-3-3281-6611

--

Fax: +81-3-3281-6607

Nihonbashi Mitsui Tower, 15/F, 2-1-1  
Nihonbashi-Muromachi

Web:  
<http://www.chugai-pharm.co.jp>

103-8324 Tokyo

E-mail: -

## Company Profile

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures                     | 2023              |                        | 2022              |                        | 2021              |                        |
|---------------------------------------|-------------------|------------------------|-------------------|------------------------|-------------------|------------------------|
|                                       | Assets            | Liabilities and equity | Assets            | Liabilities and equity | Assets            | Liabilities and equity |
| <b>Current assets</b>                 | 1,366,426,000,000 |                        | 1,336,537,000,000 |                        | 1,063,661,000,000 |                        |
| <b>Common stock capital</b>           |                   | 73,202,000,000         |                   | 73,202,000,000         |                   | 73,202,000,000         |
| <b>Fixed assets</b>                   | 566,121,000,000   |                        | 533,221,000,000   |                        | 475,033,000,000   |                        |
| <b>Equity capital of a company</b>    |                   | 1,625,580,000,000      |                   | 1,424,387,000,000      |                   | 1,188,017,000,000      |
| <b>Cash and cash equivalents</b>      | 458,674,000,000   |                        | 222,169,000,000   |                        | 267,753,000,000   |                        |
| <b>Accrued liabilities</b>            |                   | 5,739,000,000          |                   | 6,067,000,000          |                   | 5,046,000,000          |
| <b>Other assets</b>                   | -                 |                        | -                 |                        | -                 |                        |
| <b>Current liabilities</b>            |                   | 288,217,000,000        |                   | 423,730,000,000        |                   | 327,422,000,000        |
| <b>Prepayments and accrued income</b> | -                 |                        | -                 |                        | -                 |                        |
| <b>Non-current liabilities</b>        |                   | 18,749,000,000         |                   | 21,641,000,000         |                   | 23,255,000,000         |
| <b>Different income</b>               |                   | -                      |                   | -                      |                   | -                      |
| <b>Other liabilities</b>              |                   | 743,000,000            |                   | 813,000,000            |                   | 1,105,000,000          |
| <b>Total assets</b>                   | 1,932,547,000,000 | 1,932,547,000,000      | 1,869,758,000,000 | 1,869,758,000,000      | 1,538,694,000,000 | 1,538,694,000,000      |

## Balance notes

|                            | 2023   | 2022   | 2021   |
|----------------------------|--------|--------|--------|
| <b>Accounting standard</b> | IFRS   | IFRS   | IFRS   |
| <b>Employees</b>           | 7,604  | 7,771  | 7,664  |
| <b>Equity ratio</b>        | 84.12% | 76.18% | 77.21% |
| <b>Debt-equity ratio</b>   | 18.88% | 31.27% | 29.52% |

## Others

|                         | 2023   | 2022   | 2021   |
|-------------------------|--------|--------|--------|
| <b>Tax Expense Rate</b> | 26.67% | 29.51% | 27.75% |

# CHUGAI PHARMACEUTICAL CO LTD

ISIN: JP3519400000 WKN: 4519 Asset Class: Stock

## Income statement

|  | 2023              | 2022              | 2021            |
|--|-------------------|-------------------|-----------------|
| <b>Turnover</b>  | 1,111,367,000,000 | 1,259,946,000,000 | 999,758,000,000 |
| <b>Net income</b>  | 325,472,000,000   | 374,429,000,000   | 302,995,000,000 |
| <b>EBIT</b>  | 2,696,962,500     | 3,239,368,400     | 2,557,534,800   |
| <b>Operating income before taxes</b>                                 | 443,821,000,000   | 531,166,000,000   | 419,385,000,000 |
| <b>Cash Flow</b>   | 411,326,000,000   | 244,335,000,000   | 279,711,000,000 |
| <b>Net interest income</b>   | 1,696,000,000     | 122,000,000       | 117,000,000     |
| <b>Research and development expenses</b>                             | 164,764,000,000   | 148,360,000,000   | 131,276,000,000 |
| <b>Income taxes</b>  | 118,349,000,000   | 156,737,000,000   | 116,390,000,000 |
| <b>Result from investments in subsidiaries, associates and other</b> | 0                 | 0                 | 0               |
| <b>Revenues per employee</b>   | 891,549           | 989,020           | 795,736         |

## Board of Directors

|                   |                             |
|-------------------|-----------------------------|
| Christoph Franz   | Member of Supervisory Board |
| James Sabry       | Member of Supervisory Board |
| Iwaaki Taniguchi  | Member of Supervisory Board |
| Mariko Momoi      | Member of Supervisory Board |
| Masayuki Oku      | Member of Supervisory Board |
| Motoo Ueno        | Member of Supervisory Board |
| William Anderson  | Member of Supervisory Board |
| Yoichiro Ichimaru | Member of Supervisory Board |

## Members of Management Board

|                   |                               |
|-------------------|-------------------------------|
| Osamu Okuda       | Chairman of Managing Board    |
| Hisafumi Yamada   | Member of Executive Committee |
| Junichi Ebihara   | Member of Executive Committee |
| Satoko Shisai     | Member of Executive Committee |
| Shinji Hidaka     | Member of Executive Committee |
| Tetsuya Yamaguchi | Member of Executive Committee |
| Toshiaki Itagaki  | Member of Executive Committee |
| Yoshiyuki Yano    | Member of Executive Committee |